PHENTERMINE + TOPIRAMATE sold under the brand name Q-Phentop, is a combination of phentermine and topiramate used to treat obesity. Q-Phentop (Phentermine + Topiramate) is used together with dietary changes and exercise. If less than 3% weight loss is seen after 3 months it is recommended the medication be stopped. Phentermine is a stimulant and appetite suppressant and stimulant. Topiramate is an anticonvulsant that has weight loss side effects. PHENTERMINE + TOPIRAMATE was approved for medical use in the United States in 2012.
Determine the patient's BMI. BMI is calculated by dividing weight (in kilograms) by height (in meters) squared.
In adults with an initial BMI of 30 kg/m2 or greater or 27 kg/m2 or greater when accompanied by weight-related co-morbidities such as hypertension, type 2 diabetes mellitus, or dyslipidemia prescribe Q-Phentop (Phentermine + Topiramate) as follows:
Commonly reported side effects of PHENTERMINE + TOPIRAMATE include: constipation, insomnia, nasopharyngitis, paresthesia, mood disorder, sleep disorder, and xerostomia. Other side effects include: urinary tract infection, anxiety, blurred vision, depression, dizziness, fatigue, influenza, nausea, increased serum creatinine, and dysgeusia. See below for a comprehensive list of adverse effects.
Along with its needed effects, PHENTERMINE + TOPIRAMATE may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking PHENTERMINE + TOPIRAMATE:
Blood in the urine;
pain in the groin or genitals;
sharp back pain just below the ribs;
Some side effects of PHENTERMINE + TOPIRAMATE may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
View interaction reports for Q-Phentop (Phentermine + Topiramate) and the medicines listed below:
Use during pregnancy is contraindicated as this drug can cause fetal harm.
Females of reproductive potential should be advised to avoid pregnancy through abstinence or by using effective contraception during therapy.
A negative pregnancy test should be obtained before treatment initiation and monthly thereafter in females of reproductive potential.
Data from pregnancy registries and epidemiology studies indicate an up to 5-fold increased risk of oral clefts (cleft lip with or without cleft palate) with first trimester exposure to topiramate. Animal studies with clinically relevant doses of topiramate revealed embryofetal toxicity, including craniofacial defects; increased mortality; reductions in body weight and skeletal ossification; delayed physical development; and malformations in limbs, ribs, and vertebrae. Evidence of maternal toxicity, such as decreased body weight gain and mortality, were also observed in animal studies with topiramate. Animal reproduction studies have not been conducted with phentermine.
Combination phentermine and topiramate treatment in animals at doses approximately 5 to 6 times the maximum recommended human dose caused offspring toxicity and significantly lower maternal body weight gain. Offspring effects included lower survival after birth; increased limb and tail malformations; reduced body weight; and delayed growth, development, and sexual maturation without affecting learning, memory, fertility, and reproduction.
This drug can cause metabolic acidosis. Metabolic acidosis in pregnancy can result in decreased fetal growth, decreased fetal oxygenation, fetal death, and may affect the ability of the fetus to tolerate labor. If this drug is used during pregnancy or if a patient becomes pregnant while taking this drug, treatment should be discontinued immediately and the patient should be apprised of the potential hazard to a fetus.
A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. This drug may be present in human milk because topiramate and amphetamines are excreted in human milk. Phentermine has pharmacologic activity and a chemical structure similar to amphetamines.
Store Q-Phentop (Phentermine + Topiramate) at room temperature between 68-77 degrees F (20-25 degrees C) away from light and moisture. Do not store the drugs in the bathroom. Keep all drugs away from reach of children and pets.